PT  - JOURNAL ARTICLE
AU  - Haeshik S. Gorr
AU  - Lucy Yun Lu
AU  - Eric Hung
TI  - Reversal of direct oral anticoagulants: Highlights from the Anticoagulation Forum guideline
AID  - 10.3949/ccjm.88a.19133
DP  - 2021 Feb 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 98--103
VI  - 88
IP  - 2
4099  - http://www.ccjm.org/content/88/2/98.short
4100  - http://www.ccjm.org/content/88/2/98.full
SO  - Cleve Clin J Med2021 Feb 01; 88
AB  - The 2019 guideline from the Anticoagulation Forum provides clear instructions on how to use 2 agents for reversing the effects of direct oral anticoagulants (DOACs): idarucizumab for dabigatran-associated bleeding and andexanet alfa for bleeding associated with rivaroxaban and apixaban. The guideline also discusses off-label use of andexanet alfa for bleeding associated with edoxaban and betrixaban and the use of hemostatic agents such as activated prothrombin complex concentrate and 4-factor prothrombin complex concentrate. Lastly, it offers approaches for building and managing stewardship programs at the health system level.